We are live on
!
Find out more
BC
Broadwood Capital Portfolio holdings
AUM
$1.91B
1-Year Est. Return
44.39%
This Fund
S&P 500
This Quarter
Est. Return
-1.68%
1 Year Est. Return
+44.39%
3 Year Est. Return
+110.36%
5 Year Est. Return
+52.4%
10 Year Est. Return
+1,142.23%
AUM
$688M
AUM Growth
-$29.1M
(-4.1%)
Cap. Flow
+$23.1M
Cap. Flow
% of AUM
3.36%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
3
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$13.1M |
| 2 |
AXON
Axon Enterprise
AXON
|
+$11.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Monster Beverage
MNST
|
+$1.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 39.68% |
| 2 | Healthcare | 38.48% |
| 3 | Miscellaneous | 17.51% |
| 4 | Industrials | 4.34% |
Similar funds
EWS
RMA
LWMT
FIB
SAM
HPC
R
CCIA
Broadwood Capital's Q1 2018 Portfolio in Review
As of Q1 2018, Broadwood Capital held 10 positions worth $688M, down 4.1% from $717M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Broadwood Capital deployed $23.1M of net new capital in Q1 2018, adding to 3 existing holdings.
By sector, the portfolio is most concentrated in Consumer Staples at 40% of assets, down from 42% a quarter earlier, followed by Healthcare and Miscellaneous.
On the sell side, the largest reduction was Monster Beverage, an estimated $1.48M trimmed.
- Broadwood Capital added most to Insight Molecular Diagnostics in Q1 2018, an estimated $13.1M increase.
- Broadwood Capital's biggest Q1 2018 reduction was Monster Beverage, cutting an estimated $1.48M.
- Broadwood Capital's ten largest holdings make up 100% of its $688M portfolio in Q1 2018.
- Broadwood Capital opened 0 new positions and closed 1 in Q1 2018.
- Broadwood Capital's portfolio value fell 4.1% quarter-over-quarter to $688M.
Based on Broadwood Capital's 13F filing for Q1 2018, filed 15 May 2018.